MedTrace Logo

Immunophenotyping in Patients With Osteoporosis

NCT05132348 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2021-11-24

No results posted yet for this study

Summary

In addition to a medical history and clinical examination, the diagnosis of osteoporosis includes the measurement of bone surface density by means of dual X-ray absorptiometry (DXA). In addition, blood tests are performed for certain parameters, such as vitamin D, calcium, phosphate and C-reactive protein. In order to optimize osteoporosis diagnostics, the development of further specific methods is required. The modulation of the immune system seems promising in this respect, since osteoporosis is based on an inflammatory reaction. Various regulatory markers of the innate and acquired immune system, which seem to be relevant in the development of the disease, have already been detected in osteoporosis patients. This study may help to gain new insights into disease-associated immunoregulatory markers that could revolutionize both the diagnosis and therapy of osteoporosis in the long term. By means of a simple blood test, patients could be diagnosed early and without additional radiation exposure, and effective therapy options could be developed.

Conditions

  • Immunophenotyping Blood Samples of Patients With Osteoporosis

Interventions

DIAGNOSTIC_TEST

Immunological markers

Markers of blood samples of patients suffering from osteoporosis will be analyzed

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Andreas Strauß, PD Dr. · physican

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2026-02-19
Completion
2026-10-19

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132348 on ClinicalTrials.gov